Logo

Call us today 212-583-0100

ir@enzo.com    

  • Home
  • Corporate
    • Investor Information
    • About Us
    • Officers & Directors
    • Press Releases
    • Careers
  • Therapeutics
    • About ENZO Therapeutics
      • Overview
      • Our Mission
      • Our Strategy
      • Partnering
      • Maps and Directions
      • Contact Us
    • Therapeutic Market
      • Overview
      • Inflammatory Bowel Disease
      • Uveitis
      • HIV
      • Bone Disorders
      • Diabetes
    • Technologies
      • Immune Regulation
      • Gene Technology
      • Cell Signaling Modulation
    • Pipeline
      • Overview
      • Cell Signaling Modulation
        • Diabetes
        • Preclinical Studies for Bone Disorders
      • Immune Regulation
        • Alequel ™
        • Optiquel ™
      • Gene Technology
        • Stealth Vector™ HGTV43™
  • Clinical Labs
  • Life Sciences
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Feb 19, 2020 8:30am EST

Enzo Biochem Reports Publication of Study Detailing Promising Activity of Drug Candidate SK1‑I in a Model of Lupus

Feb 11, 2020 8:30am EST

Enzo Biochem Announces Significant Milestone with Approval of Proprietary GenFlex Platform

Feb 07, 2020 8:00am EST

Enzo Disappointed in Harbert’s Lawsuit Aimed at Disenfranchising Shareholders

Jan 30, 2020 8:13am EST

Enzo Comments on Harbert’s Reaction to Providing Enzo Shareholders Additional Choices

Jan 28, 2020 5:45pm EST

Enzo Biochem Proposes to Increase Size of Board and Will Appoint Additional Highly Qualified, Diverse Independent Director in Near Future

Jan 17, 2020 3:02pm EST

Enzo Biochem Comments on ISS Report

Jan 13, 2020 8:00am EST

Enzo Biochem Responds to Series of Misleading and Inaccurate Statements from Activist Hedge Fund Harbert

Dec 31, 2019 10:48am EST

Enzo Biochem Appoints Rebecca J. Fischer to Board of Directors

Dec 10, 2019 4:15pm EST

Enzo Biochem Reports Fiscal First Quarter Results

Dec 05, 2019 4:15pm EST

Enzo Biochem Issues Open Letter to Shareholders

  • Previous
  • 1…
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • …33
  • Next
RSS
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed

Meta

  • Privacy Policy
  • Intellectual Property
  • Safe Harbor Statement
  • HIPAA Policy
  • Web Feedback

Contact us

Enzo Biochem Executive Offices
81 Executive Blvd, Suite 3
Farmingdale, NY
11735
USA

212-583-0100

info@enzo.com

Copyright ©2023 Enzo Biochem Inc.